Atria Wealth Solutions Inc. Has $3.28 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Atria Wealth Solutions Inc. raised its position in Zoetis Inc. (NYSE:ZTS) by 4.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,618 shares of the company’s stock after buying an additional 643 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Zoetis were worth $3,280,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blue Bell Private Wealth Management LLC grew its holdings in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares in the last quarter. Independence Bank of Kentucky grew its holdings in Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares in the last quarter. Ramirez Asset Management Inc. acquired a new position in Zoetis in the 3rd quarter valued at $35,000. First Financial Corp IN grew its holdings in Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after buying an additional 79 shares in the last quarter. Finally, FinTrust Capital Advisors LLC lifted its position in shares of Zoetis by 42.1% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock valued at $45,000 after acquiring an additional 77 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the sale, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 2,209 shares of company stock valued at $371,293. 0.12% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ZTS. Barclays cut their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. The Goldman Sachs Group upped their target price on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Stifel Nicolaus cut their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $218.00.

Zoetis Stock Performance

NYSE:ZTS opened at $158.42 on Friday. The stock’s 50-day simple moving average is $171.79 and its 200 day simple moving average is $179.31. The firm has a market capitalization of $72.45 billion, a PE ratio of 31.25, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period in the previous year, the business posted $1.15 earnings per share. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.